Immunotherapy-Boosted Stereotactic Ablative Radiotherapy in Inoperable Early-Stage Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Radiation Oncology
• Immunotherapy

Background:

• Early-stage, inoperable non-small cell lung cancer (NSCLC) presents treatment challenges.
• Stereotactic ablative radiotherapy (SABR) is a standard treatment option.
• The integration of immune checkpoint inhibitors with SABR (iSABR) is an emerging therapeutic strategy.

Purpose of the Study:

• To evaluate the efficacy and safety of iSABR compared to SABR alone in early-stage, inoperable NSCLC.
• To analyze progression-free survival (PFS) and overall survival (OS) outcomes.
• To identify patient subgroups that may benefit most from iSABR.

Main Methods:

• A meta-analysis of seven studies involving 462 patients was conducted.
• Progression-free survival (PFS) and overall survival (OS) rates were compared between iSABR and SABR groups.
• Subgroup analyses were performed based on specific immune checkpoint inhibitors and radiation doses.

Main Results:

• iSABR demonstrated significantly improved 1-, 2-, and 3-year PFS rates compared to SABR alone.
• A trend towards improved overall survival (OS) was observed with iSABR.
• Enhanced 3-year PFS was noted with programmed death-1 (PD-1) inhibitors and higher radiation doses (≥12.5 Gy).
• A slight increase in grade ≥3 adverse events, such as pneumonitis and fatigue, was observed but deemed manageable.

Conclusions:

• iSABR shows promising efficacy with improved PFS and acceptable toxicity in early-stage, inoperable NSCLC.
• The findings support iSABR as a potential treatment option, warranting further investigation.
• Phase III randomized controlled trials are needed to confirm efficacy, optimize protocols, and establish long-term safety.